NCT04789928已完成1 期
Gentamicine-EDTA, a New Anti-biofilm Strategy for the Conservative Treatment of Catheter-related Infections
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 6
- 主要终点
- The clinical efficacy is assessed by the frequency of clinical and microbial cure after 30 days of follow-up after the end of treatment (D40)
研究概览
简要总结
Catheter-related infections are frequent. Treatment without catheter removal is difficult because of the presence of biofilm. The association of gentamicin and EDTA is active in vitro and in vivo against biofilms formed by Gram positive and Gram negative bacteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patient (≥18 year-old);
- •LTIVC in place (TIVAP or single-line tunnelled catheter);
- •LTIVC is functional (it is possible to inject an infusate, but also to draw blood from the catheter);
- •LTIVC-related bloodstream infection defined by a positive qualitative paired blood culture with a differential time to positivity ≥ 2 hours (meaning that the culture of the blood drawn from the catheter is positive at least 2 hours before the culture of the blood drawn from a peripheral vein);
- •Mono microbial infection caused by coagulase-negative staphylococci, Enterobacteriaceae or Pseudomonas aeruginosa;
- •Bacterial strain is susceptible toward gentamicin;
- •Life expectancy ≥ 3 months;
- •Physician in charge of the patient agrees to perform a conservative treatment;
- •Calculated creatinine clearance ≥ 30 mL/min;
- •Patient's informed and written consent is collected.
- •For women of reproductive age: available beta-HCG dosage (with negative result) < 72h.
- •Non-inclusion criteria:
- •A patient should not be included if he presents any of the following criteria:
- •Presence of any systemic complication (sepsis or septic shock, as defined by the sepsis-3 guidelines), or local complications (tunnel or port-pocket infection, thrombophlebitis, endocarditis, bone and joint infections related to the LTIVC-related BSI);
- •Allergy toward aminoglycosides
- •PICC-line or hemodialysis tunnelled catheter; LTIVC removal is planned within the following 3 months or LTIVC is not required for the management of the patient's underlying medical condition anymore;
- •Diagnosis of LTIVC-related bloodstream infection has been made more than 3 days ago (e.g. >72 hours between the day the first blood culture drawn from the LTIVC is positive and screening visit);
- •Systemic treatment of LTIVC-related bloodstream infection includes aminoglycosides (defined as a recent (<36 hours before screening visit) or ongoing systemic injection of aminoglycosides);
- •Low blood ionized calcium level (<1,15 μmol/L) before injecting the first dose of genta-EDTA-Na2 lock;
- •Presence of prosthetic heart valve, pacemaker or implantable defibrillator;
- •The LTIVC has been inserted less than 14 days ago;
- •Available Count blood cells < 72h with severe neutropenia (<500 polymorphonuclear cells/mm3);
- •Subject with infection caused by Staphylococcus Aureus orCandida-spp;
- •The patient is not expected to remain in hospital for at least 7 days after inclusion.
- •The administration of the lock according to the protocol (24 hours/day for 48 hours and then at least 12 hours/24 hours for 5 to 8 days) is not possible.
- •Decision by the referring physician to prescribe a preventive lock following curative Gentamicin-EDTA treatment (secondary prevention), between the end of treatment (D6/D9) and the D40 follow-up visit.
- •Previous inclusion in a study or another therapeutic protocol requiring continuous use of the catheter
- •Pregnant and breastfeeding woman;
- •Protected adult subject.
- •Inability to perform a blood peripheral venous sampling
- •Exclusion criteria
- •A patient should be excluded if he presents any of the following criteria:
- •Presence of local or systemic complication seen on venous ultrasound performed between D2 and D5 or transthoracic echocardiography performed between Day 2 and Day 7 (D2-D7);
- •GFR < 30 ml/min (between D0 and D6/9).
排除标准
- 未提供
研究组 & 干预措施
Patients with uncomplicated LTIVC-related BSI and eligible
Experimental
Patients included in this study will receive daily injection of genta-EDTA-Na2 lock associated with systemic antibiotics.
干预措施: Gentamicins-EDTA (Drug)
结局指标
主要结局
The clinical efficacy is assessed by the frequency of clinical and microbial cure after 30 days of follow-up after the end of treatment (D40)
时间窗: 30 days of follow-up after the end of treatment (D40)
Resolution of clinical signs at the end of treatment (D6 if the patient already received 72h of a previous active lock before inclusion or D9 if he received a complete 10-day course of genta-EDTA-Na2 locks) and 30 days after completion of therapy (D40)
次要结局
- The long-term clinical efficacy is assessed by the frequency of microbial cure after 90 days of follow-up after the end of treatment.(after 90 days of follow-up after the end of treatment (D100))
研究者
研究点 (6)
Loading locations...
相似试验
招募中
4 期
Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat PeritonitisPeritoneal Dialysis-associated PeritonitisNCT05971537Alice Ho Miu Ling Nethersole Hospital46
Unknown
不适用
Effects of Topical Gentamicin on the Prevention of Peritoneal Dialysis Related InfectionPeritoneal Dialysis-related InfectionNCT05251584Phramongkutklao College of Medicine and Hospital60
终止
3 期
Tamsulosin for Urinary Retention in Hospitalized Older WomenUrinary RetentionNCT01747993Assistance Publique - Hôpitaux de Paris34
已完成
不适用
Antimicrobial urinary catheter safety studySpecialty: Renal disorders, Primary sub-specialty: Renal disordersUKCRC code/ Disease: Renal and Urogenital/ Other disorders of kidney and ureterUrological and Genital DiseasesLong-term (over 28 days) long-term urethral urinary catheter useISRCTN12606737niversity of Nottingham60
已完成
1 期
A Novel Catheter Lock Solution for Treatment of Tunneled Hemodialysis Catheter-Associated BacteremiaEnd-Stage Renal DiseaseHemodialysis Catheter-associated InfectionNCT00614679University of California, San Diego18